Cargando…
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers
INTRODUCTION: At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations...
Autores principales: | Dam, Erik B, Loog, Marco, Christiansen, Claus, Byrjalsen, Inger, Folkesson, Jenny, Nielsen, Mads, Qazi, Arish A, Pettersen, Paola C, Garnero, Patrick, Karsdal, Morten A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745797/ https://www.ncbi.nlm.nih.gov/pubmed/19630944 http://dx.doi.org/10.1186/ar2774 |
Ejemplares similares
-
Serological identification of fast progressors of structural damage with rheumatoid arthritis
por: Siebuhr, Anne Sofie, et al.
Publicado: (2013) -
Distribution, Size, and Shape of Abdominal Aortic Calcified Deposits and Their Relationship to Mortality in Postmenopausal Women
por: Ganz, Melanie, et al.
Publicado: (2012) -
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin
por: Karsdal, Morten A, et al.
Publicado: (2008) -
Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis
por: Bihlet, Asger Reinstrup, et al.
Publicado: (2019) -
Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis
por: Bay-Jensen, Anne-Christine, et al.
Publicado: (2021)